Spark Therapeutics, Inc. announced the closing of an underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission. The aggregate net proceeds to Spark in the offering were approximately $128 million, after deducting underwriting discounts and before offering expenses.
Spark, a fully-integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark's validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases; liver-associated diseases, such as hemophilia; and neurodegenerative diseases.
For more information, read Spark's press release.